Redlight Guide

Age-related macular degeneration

Photobiomodulation for age-related macular degeneration

Evidence for specialized ophthalmic photobiomodulation devices in non-exudative age-related macular degeneration.

Study count

Cited reviews include two RCTs in a Cochrane review and a later three-RCT meta-analysis with 247 eyes.

Evidence grade

low

Panel relevance

not-panel-replicable

Bottom line

AMD belongs in the evidence library only as specialized ophthalmic PBM, not consumer panel advice.

Consensus: Evidence remains uncertain: some statistical signals exist, but clinical meaningfulness and risk of bias are unresolved.

What the studies found

  • A 2021 Cochrane review found no meaningful clinical difference in visual acuity at 12 months.
  • A 2024 meta-analysis found small statistical improvements in visual acuity and drusen volume but not clinically significant benefits.
  • High risk of bias and insufficient sample sizes remain major limitations.

Dosage and timing

WavelengthsNot settled nm
IrradianceNot settled
FluenceNot settled
Session timeDevice-specific.
FrequencyOphthalmology-device specific.
DurationDevice-specific.
TimingNo general time-of-day consensus.
Treatment areaRetina/eyes via ophthalmic systems.
Device typesSpecialized ophthalmic PBM devices.
NotesConsumer panel eye exposure should not be recommended.
  • No home panel protocol exists.
  • Ophthalmic PBM protocols are device-specific and safety-critical.
  • Eye protection and ophthalmologist supervision are essential.

Caveats

  • AMD is a serious eye disease.
  • Never suggest looking into a red light panel.
  • This category should avoid consumer dosing instructions.

Cited peer-reviewed sources

systematic-review 2 included studies Evidence: low; direction: unclear Panel relevance: not-panel-replicable Wavelengths: Not reported Dose/timing: Ophthalmology-device specific / Ophthalmology-device specific Area: Eyes/retina Device: Specialized ophthalmic PBM systems Source

Henein C, Steel DH. Cochrane Database of Systematic Reviews. 2021.

A Cochrane review found uncertainty about whether PBM slows progression of non-exudative AMD.

Source

meta-analysis 3 included studies Evidence: low; direction: mixed Panel relevance: not-panel-replicable Wavelengths: Not reported Dose/timing: Ophthalmology-device specific / Ophthalmology-device specific Area: Eyes/retina via ophthalmic PBM systems Device: Specialized ophthalmic photobiomodulation devices Source

Rassi TNO, Barbosa LM, Pereira S, et al. International Journal of Retina and Vitreous. 2024.

A 2024 meta-analysis found statistically significant changes in some dry AMD outcomes, but not clinically meaningful benefits and high risk of bias.

Source

Last reviewed: 2026-06-15